摘要
目的探究孟鲁司特钠联合布地奈德雾化剂治疗小儿哮喘的疗效及对血清C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)的影响。方法82例小儿哮喘患儿,按照抽签方法分为对照组和观察组,每组41例。所有患儿入院后均给予吸氧、平喘、止咳等常规治疗,对照组在常规治疗基础上给予布地奈德雾化剂治疗,观察组在常规治疗基础上采取孟鲁司特钠联合布地奈德雾化剂治疗。比较两组治疗效果、治疗前后血清炎症因子(CRP、TNF-α、IL-6)及肺功能指标[第1秒用力呼气容积(FEV1)、呼气高峰流量(PEFR)、第1秒用力呼气容积/用力肺活量(FEV1/FVC)]水平。结果观察组治疗总有效率95.12%高于对照组的80.49%,差异有统计学意义(P<0.05)。治疗后,观察组血清CRP、TNF-α、IL-6水平分别为(3.89±0.45)mg/L、(88.56±10.21)ng/ml、(89.56±10.56)ng/L,低于治疗前的(9.56±1.44)mg/L、(165.56±19.56)ng/ml、(119.56±9.98)ng/L;对照组血清CRP、TNF-α、IL-6水平分别为(5.02±1.09)mg/L、(98.56±9.56)ng/ml、(98.45±11.26)ng/L,低于治疗前的(10.11±2.11)mg/L、(168.45±20.63)ng/ml、(120.23±11.56)ng/L;观察组CRP、TNF-α、IL-6水平低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组的FEV1、PEFR、FEV1/FVC水平分别为(2.89±0.45)L、(3.36±0.45)L/s、(64.56±10.21)%,高于治疗前的(1.98±0.23)L、(1.55±0.31)L/s、(55.48±5.48)%;对照组的FEV1、PEFR、FEV1/FVC水平分别为(2.35±0.31)L、(2.88±0.37)L/s、(58.56±9.89)%,高于治疗前的(1.89±0.22)L、(1.42±0.29)L/s、(54.36±4.98)%;观察组的FEV1、PEFR、FEV1/FVC水平高于对照组,差异有统计学意义(P<0.05)。结论对小儿哮喘给予孟鲁司特钠联合布地奈德雾化剂治疗效果较好,可降低血清炎症因子水平,减轻患儿炎症反应,同时对肺功能改善有积极作用。
Objective To investigate the efficacy of montelulast sodium combined with budesonide atomizer in the treatment of childhood asthma and its influence on serum C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6).Methods A total of 82 children with asthma were divided into control group and observation group according to lottery method,with 41 cases in each group.All children received conventional therapy of oxygen inhalation,asthma and cough relief.The control group was also treated with budesonide atomizer,and the observation group was also treated with montelulast sodium combined with budesonide atomizer.The therapeutic effect,serum inflammatory factors(CRP,TNF-α,IL-6),pulmonary function indicators[forced expiratory volume in 1 second(FEV1),peak expiratory flow rate(PEFR),FEV1/FVC]were compared between the two groups.Results The total effective rate 95.12%of the observation group was higher than 80.49%of the control group,and the difference was statistically significant(P<0.05).After treatment,the serum CRP,TNF-αand IL-6 of the observation group were(3.89±0.45)mg/L,(88.56±10.21)ng/ml and(89.56±10.56)ng/L,which were lower than(9.56±1.44)mg/L,(165.56±19.56)ng/ml and(119.56±9.98)ng/L before treatment;the serum CRP,TNF-αand IL-6 of the control group were(5.02±1.09)mg/L,(98.56±9.56)ng/ml and(98.45±11.26)ng/L,which were lower than(10.11±2.11)mg/L,(168.45±20.63)ng/ml and(120.23±11.56)ng/L before treatment;the CRP,TNF-αand IL-6 of the observation group were lower than those of the control group.All the difference was statistically significant(P<0.05).After treatment,the FEV1,PEFR,and FEV1/FVC of the observation group were(2.89±0.45)L,(3.36±0.45)L/s and(64.56±10.21)%,which were higher than(1.98±0.23)L,(1.55±0.31)L/s and(55.48±5.48)%before treatment;the FEV1,PEFR,and FEV1/FVC of the control group were(2.35±0.31)L,(2.88±0.37)L/s and(58.56±9.89)%,which were higher than(1.89±0.22)L,(1.42±0.29)L/s and(54.36±4.98)%before treatment;the FEV1,PEFR,and FEV1/FVC of the observation group were higher than those of the control group.All the difference was statistically significant(P<0.05).Conclusion Combination of montelulast sodium and budesonide atomizer shows good therapeutic effect on childhood asthma,which can lower the level of serum inflammatory factors,reduce the inflammatory response in children,and have a positive effect on the improvement of lung function.
作者
冯中平
FENG Zhong-ping(Department of Pediatrics,Shanghai Yangsi Hospital,Shanghai 201102,China)
出处
《中国现代药物应用》
2021年第10期17-20,共4页
Chinese Journal of Modern Drug Application
